May 22, 2014
/PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the installation of its 500
TomoTherapy® System at the grand opening of Palo Verde Cancer Center –
The System, a TomoHDA™ model, is the only radiation therapy device at the new center, which also offers medical oncology services. The center's decision to invest in the latest TomoTherapy offering reflects growing confidence industry-wide in the enhanced performance and clinical versatility of the technology, long-known for its superior radiation therapy delivery, precision and treatment quality.
"Our latest innovations in TomoTherapy technology, from faster treatment planning to more efficient treatment delivery, make it the ideal solution for fully-integrated cancer centers such as the Palo Verde Cancer Center –
Joshua H. Levine
, president and chief executive officer of Accuray. "We are pleased to partner with the
team in making this important technology an option for all their patients."
The TomoHDA System offers fast, reliable, accurate and flexible treatment planning and delivery for each patient, regardless of the location, size and complexity of the tumor. It is an ideal option for treating a wide range of cancers, including recurrent disease in patients who have already received maximum radiation doses to critical organs.
"We analyzed all radiation therapy offerings when planning our new, fully-integrated cancer center, and chose the TomoHDA System for its outstanding speed, performance and simplicity," said Dr.
, Medical Director of Radiation Oncology at Palo Verde Cancer Center –
. "We wanted technology that would allow us to treat the broadest range of patients, and we find TomoHDA treatment planning to be flexible and easy-to-use. After working with older TomoTherapy equipment for nearly a decade and with the Accuray
at our affiliate site, the Phoenix CyberKnife and Radiation Oncology Center, we are confident that this next generation TomoHDA technology will allow us to treat more patients effectively. The System is the perfect complement to our existing treatment offerings and will further ensure we won't have to turn away any difficult-to-treat patients."
About TomoTherapy TomoHDA
sets a new standard in radiation oncology, with helical and direct-angle delivery of image-guided 3D conformal and intensity-modulated radiation therapy. With the new VoLO™ Treatment Planning and TomoEDGE™ Dynamic Jaws technologies, the TomoHDA System significantly improves workflow and delivery efficiency, while also further improving treatment quality.
More than 1,500 papers, posters and abstracts have been published on the application of the TomoTherapy System across a variety of clinical indications including breast, lung, head and neck, and prostate cancers, globally. The emergent body of evidence demonstrates the inherent advantages of the technology's CT scanner-based platform compared to conventional radiotherapy systems.